Abstract
Background: The use of Lactobacillus probiotics may confer beneficial effects
on an individual’s health, such as the ability to act against fungi of the genus Candida.
There are about 200 species of those yeasts, and they can develop candidiasis infections,
which affect about 75% of adult women.
Objective: This study aimed to raise articles that investigated the potential action of several
Lactobacillus strains in front of Candida species.
Methods: For this review, 15 articles published between 2015 and 2020 were studied.
Results: The results showed the Lactobacillus species L. paracasei, L. acidophilus, L. helveticus,
L. rhamnosus, L. reuteri, and L. gasseri have the potential action to inhibit the
growth and quantity of colony-forming units of Candida species in vitro studies. Further,
they can reduce the rate of candidiasis recurrence and increase the cure rate, mainly when
associated with traditional pharmacotherapy, as observed in vivo studies.
Conclusion: The time of use and the strain of Lactobacillus probiotics can also be determining
factors for the efficiency in the treatment against Candida species, suggesting that a
long time of use of Lactobacillus probiotics is directly associated with a better result.
Keywords:
Candida, Lactobacillus, probiotics, effects, candidiasis, potential action.
Graphical Abstract
[4]
Álvares CA, Svidzinski TIE, Consolaro MEL. Vulvovaginal candidiasis: Predisposing factors of the host and virulence of yeasts. J Bras Patol Med Lab 2007; 43(5): 319-27.
[5]
Barbedo LM, Sgarbi DBG. Candidiasis. DST J Bras 2010; 22: 22-83.
[10]
Current approach to vulvovaginal candidiasis. DST J Bras 2001; 13(4): 3-5.
[11]
Study of the applicability of the total protein quantification
assay in SIRC cells in the evaluation of the potential
for eye irritation of shampoos and tensoactives. Thesis (Master) - Oswaldo Cruz Foundation, Sérgio
Arouca National School of Public Health Rio de
Janeiro 2006.
[16]
Carmo MS, Noronha FMF, Arrruda MO, et al. Lacobacillus fermentum ATCC 23271 displays in vitro inhibitory activities against Candida spp. Front Microbiol 2016; 7: 1722.
[17]
Wang S, Wang Q, Yang E, Yan L, Li T, Zhuang H. Antimicrobial compounds produced by vaginal Lactobacillus crispatus are able to strongly inhibit Candida albicans growth, hyphal formation and regulate virulence-related gene expressions. Front Microbiol 2017; 8: 564.
[18]
Kumherová M, Veselá K, Kosová K, Mašata J, Horáčková Š, Šmidrkal J. Novel potential probiotic Lactobacilli for prevention and treatment of vulvovaginal infections. Probiotics Antimicrob Proteins 2020; 13(1): 163-72.
[19]
Deida F, Amorouso A, Allesina S, et al. In vitro activity of Lactobacillus fermentum LF5 against different Candida species and Gardnerella vaginalis, a new perspective to approach mixed vaginal infections. Proceedings from the 8th probiotics, prebiotics & new foods for microbiota and human health meeting held in Rome, Italy on September 13-15. J Clin Gastroenterol 2015; S168-70.
[20]
Liao H, Liu S, Wang H, Su H, Liu Z. Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus caseiin the murine model of vulvovaginal candidiasis. BMC Microbiol 2019; 19: 7.
[21]
Davar R, Nokhostin F, Eftekhar M, Sekhavat L, Zadeh MB, Shamsi F. Comparing the recurrence of vulvovaginal Candidiasis in patients undergoing prophylactic treatment with probiotic and placebo during the 6 months. Probiotics Antimicrob Proteins 2016; 8(3): 130-3.
Download PDF Flyer